# Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine

> **NCT07661940** · PHASE2 · RECRUITING · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 120 (estimated)

## Conditions studied

- AKI - Acute Kidney Injury

## Interventions

- **DRUG:** SP16-3M
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07661940
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-14
- **Primary completion:** 2029-05
- **Final completion:** 2029-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661940, "Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07661940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*